Kontzias A, Zarabi SK, Calabrese C, Wang Y, Judis L, Yao Q, et al. Somatic mosaicism in adult-onset TNF receptor-associated periodic syndrome (TRAPS). Mol Genet Genomic Med. 2019;7:e791.

Article  PubMed  PubMed Central  Google Scholar 

Lachmann HJ, Papa R, Gerhold K, Obici L, Touitou I, Cantarini L, et al. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis. 2014;73:2160–7.

Article  CAS  PubMed  Google Scholar 

Hosono K, Matsumoto K, Shimbo M, Tsumiyama I, Kato C. Real-world safety and effectiveness of canakinumab in patients with tumour necrosis factor receptor-associated periodic syndrome or hyperimmunoglobulinaemia D syndrome: interim results from post-marketing surveillance in Japan. Mod Rheumatol. 2023;33:381–91.

Article  PubMed  Google Scholar 

Gaggiano C, Vitale A, Obici L, Merlini G, Soriano A, Viapiana O, et al. Clinical features at onset and genetic characterization of pediatric and adult patients with TNF-α receptor-associated periodic syndrome (TRAPS): a series of 80 cases from the AIDA network. Mediators Inflamm. 2020;2020:8562485.

Article  PubMed  PubMed Central  Google Scholar 

Cudrici C, Deuitch N, Aksentijevich I. Revisiting TNF receptor-associated periodic syndrome (TRAPS): current perspectives. Int J Mol Sci. 2020;21:3263.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zegarska J, Wiesik-Szewczyk E, Hryniewiecka E, Wolska-Kusnierz B, Soldacki D, Kacprzak M, et al. Tumor necrosis factor receptor-associated periodic syndrome (TRAPS) with a new pathogenic variant in TNFRSF1A gene in a family of the adult male with renal AA amyloidosis—diagnostic and therapeutic challenge for clinicians. J Clin Med. 2021;10:465.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Klinaki E, Nezos A, Tzioufas AG, Tsolia MN, Maritsi DN. Diagnosis and management of a young girl with tumor necrosis factor receptor associated periodic syndrome (TRAPS) linked to a novel mutation. Cureus. 2020;12:e10766.

PubMed  PubMed Central  Google Scholar 

Balci S, Kisla Ekinci RM, Melek E, Atmis B, Bisgin A, Yilmaz M. Phenotypic variability in two patients with tumor necrosis factor receptor associated periodic fever syndrome emphasizes a rare manifestation: immunoglobulin A nephropathy. Eur J Med Genet. 2020;63:103780.

Article  PubMed  Google Scholar 

Aksentijevich I, Galon J, Soares M, Mansfield E, Hull K, Oh HH, et al. The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype–phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet. 2001;69:301–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yasumura J, Shimizu M, Toma T, Yashiro M, Yachie A, Okada S. Clinical significance of serum soluble TNF receptor I/II ratio for the differential diagnosis of tumor necrosis factor receptor-associated periodic syndrome from other autoinflammatory diseases. Front Immunol. 2020. https://doi.org/10.3389/fimmu.2020.576152.

Article  PubMed  PubMed Central  Google Scholar 

Stojanov S, Dejaco C, Lohse P, Huss K, Duftner C, Belohradsky BH, et al. Clinical and functional characterisation of a novel TNFRSF1A c.605T>A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment. Ann Rheum Dis. 2008;67:1292–8.

Infevers. TNFRSF1A (NM_001065.4) sequence variants. Available at: https://infevers.umai-montpellier.fr/web/search.php?n=2. Accessed 22 Aug 2024.

Akagi T, Hiramatsu-Asano S, Ikeda K, Hirano H, Tsuji S, Yahagi A, et al. TRAPS mutations in TNFRSF1A decrease the responsiveness to TNFalpha via reduced cell surface expression of TNFR1. Front Immunol. 2022;13:926175.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Papa R, Lane T, Minden K, Touitou I, Cantarini L, Cattalini M, et al. INSAID variant classification and Eurofever criteria guide optimal treatment strategy in patients with TRAPS: data from the Eurofever registry. J Allergy Clin Immunol Pract. 2021;9:783-91.e4.

Article  CAS  PubMed  Google Scholar 

Van Gijn ME, Ceccherini I, Shinar Y, Carbo EC, Slofstra M, Arostegui JI, et al. New workflow for classification of genetic variants’ pathogenicity applied to hereditary recurrent fevers by the International Study Group for Systemic Autoinflammatory Diseases (INSAID). J Med Genet. 2018;55:530–7.

Article  PubMed  Google Scholar 

Gattorno M, Hofer M, Federici S, Vanoni F, Bovis F, Aksentijevich I, et al. Classification criteria for autoinflammatory recurrent fevers. Ann Rheum Dis. 2019;78:1025–32.

Article  CAS  PubMed  Google Scholar 

Hansmann S, Lainka E, Horneff G, Holzinger D, Rieber N, Jansson AF, et al. Consensus protocols for the diagnosis and management of the hereditary autoinflammatory syndromes CAPS, TRAPS and MKD/HIDS: a German PRO-KIND initiative. Pediatr Rheumatol Online J. 2020;18:17.

Article  PubMed  PubMed Central  Google Scholar 

Aróstegui JI, Solís P, Aldea A, Cantero T, Rius J, Bahíllo P, et al. Etanercept plus colchicine treatment in a child with tumour necrosis factor receptor-associated periodic syndrome abolishes auto-inflammatory episodes without normalising the subclinical acute phase response. Eur J Pediatr. 2005;164:13–6.

Article  PubMed  Google Scholar 

Cantarini L, Rigante D, Lucherini OM, Cimaz R, Laghi Pasini F, Baldari CT, et al. Role of etanercept in the treatment of tumor necrosis factor receptor-associated periodic syndrome: personal experience and review of the literature. Int J Immunopathol Pharmacol. 2010;23:701–7.

Article  CAS  PubMed  Google Scholar 

Kuemmerle-Deschner JB, Gautam R, George AT, Raza S, Lomax KG, Hur P. Systematic literature review of efficacy/effectiveness and safety of current therapies for the treatment of cryopyrin-associated periodic syndrome, hyperimmunoglobulin D syndrome and tumour necrosis factor receptor-associated periodic syndrome. RMD Open. 2020;6:e001227.

Article  PubMed  PubMed Central  Google Scholar 

Chandrakasan S, Chiwane S, Adams M, Fathalla BM. Clinical and genetic profile of children with periodic fever syndromes from a single medical center in South East Michigan. J Clin Immunol. 2014;34:104–13.

Article  PubMed  Google Scholar 

European Medicines Agency (EMA). Enbrel (etanercept) 25 mg powder for solution for injection. Summary of Product Characteristics (SmPC). Available at: https://www.ema.europa.eu/en/documents/product-information/enbrel-epar-product-information_en.pdf. Accessed 17 Dec 2024.

European Medicines Agency (EMA). Canakinumab (ILARIS). Summary of Product Characteristics (SmPC). https://www.ema.europa.eu/en/documents/product-information/ilaris-epar-product-information_en.pdf. Accessed 17 Dec 2024.

US Food & Drug Administration (FDA). Highlights of prescribing information: ILARIS® (canakinumab) injection, for subcutaneous use. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125319s110lbl.pdf. Accessed May 2025.

De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, et al. Canakinumab for the treatment of autoinflammatory recurrent fever syndromes. N Engl J Med. 2018;378:1908–19.

Article  PubMed  Google Scholar 

Gattorno M, Obici L, Penadés IC, Kallinich T, Benseler S, Dekker E, et al. Long-term efficacy and safety of canakinumab in patients with tumor necrosis factor receptor-associated periodic syndrome: results from a phase III trial. Arthritis Rheumatol. 2024;76:304–12.

Article  CAS  PubMed  Google Scholar 

Lachmann HJ, Lauwerys B, Miettunen P, Kallinich T, Jansson A, Rosner I, et al. Canakinumab improves patient-reported outcomes in children and adults with autoinflammatory recurrent fever syndromes: results from the CLUSTER trial. Clin Exp Rheumatol. 2021;39(Suppl 132):51–8.

Article  PubMed  Google Scholar 

Kuemmerle-Deschner JB, Kallinich T, Henes J, Kortus-Götze B, Oommen PT, Rech J, et al. Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases: results from the interim analysis of the RELIANCE registry. RMD Open. 2024;10:e003890.

Article  PubMed  PubMed Central  Google Scholar 

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–24.

Article  PubMed  PubMed Central  Google Scholar 

Clinvar. TNFRSF1A [gene]. Available at: https://www.ncbi.nlm.nih.gov/clinvar/?term=TNFRSF1A%5Bgene%5D&redir=gene. Accessed 11 Sep 2024.

Romano M, Arici ZS, Piskin D, Alehashemi S, Aletaha D, Barron K, et al. The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. Arthritis Rheumatol. 2022;74:1102–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Welzel T, Benseler SM, Kuemmerle-Deschner JB. Management of monogenic IL-1-mediated autoinflammatory diseases in childhood. Front Immunol. 2021;12:516427.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hur P, Lomax KG, Ionescu-Ittu R, Manceur AM, Xie J, Cammarota J, et al. Reasons for canakinumab initiation among patients with periodic fever syndromes: a retrospective medical chart review from the United States. Pediatr Rheumatol Online J. 2021;19:143.

Article